AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
parecoxib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| selective cyclo-oxygenase inhibitors | 2063 | 198470-84-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Parecoxib is a prodrug of valdecoxib. Valdecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor within the clinical dose range. Cyclooxygenase is responsible for generation of prostaglandins. Two isoforms, COX-1 and COX-2, have been identified. COX-2 is the isoform of the enzyme that has been shown to be induced by pro-inflammatory stimuli and has been postulated to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 40 | mg | P |
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK2,JAK2,MAP2K6,MAP3K21,MAP3K7,MAPK7,MAPK9,MAPKAPK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PIK3CG,PRKDC,SIK2,SIK3,STK33,TEK,TTK | 35 | |||
| kinase-selectivity-class | AXL,ERBB2,GRK2,MAPK7 | 4 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 22, 2002 | EMA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Negative pressure pulmonary oedema | 109.91 | 80.92 | 15 | 240 | 610 | 42620470 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Negative pressure pulmonary oedema | 110.35 | 58.96 | 15 | 550 | 684 | 110588050 |
| Anaphylactic reaction | 66.26 | 58.96 | 24 | 541 | 114276 | 110474458 |
| Neuromuscular block prolonged | 63.68 | 58.96 | 10 | 555 | 1237 | 110587497 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M01AH04 | MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS Coxibs |
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D000893 | Anti-Inflammatory Agents |
| MeSH PA | D000894 | Anti-Inflammatory Agents, Non-Steroidal |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D016861 | Cyclooxygenase Inhibitors |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018501 | Antirheumatic Agents |
| MeSH PA | D018689 | Sensory System Agents |
| MeSH PA | D018712 | Analgesics, Non-Narcotic |
| MeSH PA | D052246 | Cyclooxygenase 2 Inhibitors |
| CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory drug |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:35481 | non-narcotic analgesic |
| CHEBI has role | CHEBI:50266 | prodrug |
| CHEBI has role | CHEBI:50629 | cyclooxygenase 2 inhibitor |
Related Drugs by ATC class:
M01AH Coxibs 6 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Acute postoperative pain | indication | 107401000119105 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.39 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Prostaglandin G/H synthase 2 | Enzyme | INHIBITOR | IC50 | 8.30 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Prostaglandin G/H synthase 1 | Enzyme | INHIBITOR | IC50 | 3.85 | SCIENTIFIC LITERATURE | ||||
| Nuclear receptor subfamily 4 group A member 2 | Nuclear other | IC50 | 4.87 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D03716 | KEGG_DRUG |
| 198470-85-8 | SECONDARY_CAS_RN |
| C0915142 | UMLSCUI |
| CHEBI:73038 | CHEBI |
| PXB | PDB_CHEM_ID |
| CHEMBL1206690 | ChEMBL_ID |
| CHEMBL296913 | ChEMBL_ID |
| DB08439 | DRUGBANK_ID |
| C409945 | MESH_SUPPLEMENTAL_RECORD_UI |
| 119828 | PUBCHEM_CID |
| 2895 | IUPHAR_LIGAND_ID |
| 7816 | INN_ID |
| 9TUW81Y3CE | UNII |
| 279950 | RXNORM |
| 009631 | NDDF |
| 009632 | NDDF |
| 395289008 | SNOMEDCT_US |
| 409135005 | SNOMEDCT_US |
| 734520005 | SNOMEDCT_US |
| 9TUW81Y3CE | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Parecoxib Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0048 | INJECTION, POWDER, FOR SOLUTION | 40 mg | INTRAVENOUS | Export only | 1 sections |